{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:48:20Z","timestamp":1773038900816,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Public Health"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00038-020-01467-3","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T11:02:42Z","timestamp":1598698962000},"page":"1181-1191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Late presenters among minority patients with chronic hepatitis C infection in the USA"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-6688","authenticated-orcid":false,"given":"Calvin Q.","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Gayam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milana","family":"Normatov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bazhena","family":"Fidman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"key":"1467_CR5","unstructured":"AASLD, HCV guidelines. \n                  https:\/\/www.hcvguidelines.org\/evaluate\/monitoring\n                  \n                . Accessed August 16 2020"},{"issue":"2","key":"1467_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/jamainternmed.2014.6502","volume":"175","author":"AA Butt","year":"2015","unstructured":"Butt AA, Yan P, Re VL, Rimland D, Goetz MB, Leaf D et al (2015) Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Int Med 175(2):178\u2013185","journal-title":"JAMA Int Med"},{"issue":"1","key":"1467_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/gast.2001.25540","volume":"121","author":"JB Dixon","year":"2001","unstructured":"Dixon JB, Bhathal PS, O\u2019brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121(1):91\u2013100","journal-title":"Gastroenterology"},{"issue":"1","key":"1467_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12913-017-2095-5","volume":"17","author":"AM Falla","year":"2017","unstructured":"Falla AM, Veldhuijzen IK, Ahmad AA, Levi M, Richardus JH (2017) Language support for linguistic minority chronic hepatitis B\/C patients: an exploratory study of availability and clinicians\u2019 perceptions of language barriers in six European countries. BMC Health Serv Res 17(1):150","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"1467_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10900-017-0335-6","volume":"42","author":"EB Feldman","year":"2017","unstructured":"Feldman EB, Balise R, Schiff E, Whitehead N, Thomas E (2017) Barriers to hepatitis C screening in a minority population: a comparison of hepatitis C and human immunodeficiency virus screening rates at a community STD clinic in Miami, Florida. J Commun Health 42(5):921\u2013925","journal-title":"J Commun Health"},{"key":"1467_CR7","unstructured":"Kaiser Family Foundation, \n                  https:\/\/www.kff.org\/medicaid\/stateindicator\/distribution-by-raceethnicity-4\n                  \n                . Accessed August 16, 2020"},{"issue":"6","key":"1467_CR8","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s10903-016-0350-1","volume":"18","author":"MH Kuniholm","year":"2016","unstructured":"Kuniholm MH, Jung M, Del Amo J, Talavera GA, Thyagarajan B, Hershow RC et al (2016) Awareness of hepatitis C virus seropositivity and chronic infection in the Hispanic Community Health Study\/Study of Latinos (HCHS\/SOL). J Immigr Minor Health 18(6):1257\u20131265","journal-title":"J Immigr Minor Health"},{"issue":"1","key":"1467_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12916-017-0856-y","volume":"15","author":"S Mauss","year":"2017","unstructured":"Mauss S, Pol S, Buti M, Duffell E, Gore C, Lazarus JV et al (2017) Late presentation of chronic viral hepatitis for medical care: a consensus definition. BMC Med 15(1):92","journal-title":"BMC Med"},{"issue":"5","key":"1467_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/hep.27365","volume":"61","author":"AC Moorman","year":"2015","unstructured":"Moorman AC, Xing J, Ko S, Rupp LB, Xu F, Gordon SC et al (2015) Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): missed opportunities for intervention. Hepatology 61(5):1479\u20131484","journal-title":"Hepatology"},{"issue":"5","key":"1467_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","volume":"34","author":"T Poynard","year":"2001","unstructured":"Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J (2001) Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34(5):730\u2013739","journal-title":"J Hepatol"},{"key":"1467_CR12","unstructured":"The state of Medicaid Access, Preliminary finding. National Summary Report (Nov 14, 2016). \n                  www.chlpi.org\n                  \n                . Accessed August 16, 2020"},{"issue":"22","key":"1467_CR13","doi-asserted-by":"publisher","first-page":"e3719","DOI":"10.1097\/MD.0000000000003719","volume":"95","author":"P Vutien","year":"2016","unstructured":"Vutien P, Hoang J, Brooks L Jr, Nguyen NH, Nguyen MH (2016) Racial disparities in treatment rates for chronic hepatitis C: analysis of a population-based cohort of 73,665 patients in the United States. Medicine 95(22):e3719","journal-title":"Medicine"},{"key":"1467_CR6","unstructured":"WHO, Hepatitis C update, October 2017. Accessed August 16, 2020"},{"issue":"9","key":"1467_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41395-018-0033-8","volume":"113","author":"RJ Wong","year":"2018","unstructured":"Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C et al (2018a) Race\/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. Am J Gastroenterol 113(9):1329\u20131338","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1467_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17765-5","volume":"8","author":"A Wong","year":"2018","unstructured":"Wong A, Le A, Lee M-H, Lin Y-J, Nguyen P, Trinh S et al (2018b) Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. Sci Rep 8(1):1\u20138","journal-title":"Sci Rep"},{"key":"1467_CR16","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030. May 2016. Available at \n                  http:\/\/www.who.int\/hepatitis\/publications\/hepelimination-by-2030-brief\/en\/\n                  \n                . Accessed August 16, 2020"},{"issue":"6","key":"1467_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/jvh.12506","volume":"23","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Bacon B, Dieterich D, Flamm SL, Kowdley K, Milligan S et al (2016) Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. J Viral Hepatitis 23(6):447\u2013454","journal-title":"J Viral Hepatitis"},{"issue":"11","key":"1467_CR18","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/cid\/cix1106","volume":"66","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Br\u00e4u N et al (2018) Hepatitis C in patients with minimal or no hepatic fibrosis: the impact of treatment and sustained virologic response on patient-reported outcomes. Clin Infect Dis 66(11):1742\u20131750","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00038-020-01467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00038-020-01467-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00038-020-01467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T05:04:48Z","timestamp":1599973488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00038-020-01467-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1007\/s00038-020-01467-3","relation":{},"ISSN":["1661-8556","1661-8564"],"issn-type":[{"value":"1661-8556","type":"print"},{"value":"1661-8564","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,29]]},"assertion":[{"value":"30 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Pan received grants from Gilead. He also serves as a consultant or advisor for Gilead and speaker for Gilead, Abbvie and Intercept. Other authors have nothing to be disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}